Last edition
News about "Mismatch Repair Deficient"
GSK's Jemperli Receives FDA Priority Review for dMMR/MSI-H Locally Advanced Rectal Cancer
GSK’s Jemperli has received FDA priority review for previously untreated dMMR/MSI-H locally advanced rectal cancer, following positive phase 2 AZUR-1 results.
Mismatch Repair Deficient | 26/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members